US · UTHR
United Therapeutics Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Silver Spring, MD 20910
- Website
- unither.com
Price · as of 2025-12-31
$570.40
Market cap 22.79B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $361.51 | -36.62% |
| Intrinsic Value(DCF) | $283.08 | -50.37% |
| Graham-Dodd Method(GD) | $310.83 | -45.51% |
| Graham Formula(GF) | $550.44 | -3.5% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $46.85 | $83.52 | $761.16 | $35.51 | $114.84 |
| 2012 | $61.73 | $116.82 | $557.64 | $50.04 | $177.21 |
| 2013 | $100.96 | $121.25 | $687.61 | $43.26 | $101.70 |
| 2014 | $163.30 | $181.24 | $659.96 | $61.35 | $161.38 |
| 2015 | $124.64 | $193.40 | $475.25 | $105.38 | $302.17 |
| 2016 | $149.45 | $217.48 | $188.37 | $123.75 | $272.76 |
| 2017 | $115.34 | $204.46 | $134.57 | $94.94 | $149.90 |
| 2018 | $110.61 | $171.99 | $78.87 | $131.11 | $37.57 |
| 2019 | $98.26 | $100.65 | $29.73 | $50.91 | $5.71 |
| 2020 | $159.50 | $319.15 | $70.73 | $134.42 | $121.43 |
| 2021 | $173.00 | $194.37 | $72.49 | $140.53 | $224.01 |
| 2022 | $228.77 | $218.67 | $142.59 | $184.73 | $356.25 |
| 2023 | $243.05 | $223.36 | $225.90 | $232.37 | $577.67 |
| 2024 | $315.91 | $270.24 | $365.26 | $274.05 | $811.83 |
| 2025 | $513.82 | $361.51 | $106.07 | $310.83 | $550.44 |
AI valuation
Our deep-learning model estimates United Therapeutics Corporation's (UTHR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $361.51
- Current price
- $570.40
- AI upside
- -36.62%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$283.08
-50.37% upside
Graham-Dodd
$310.83
-45.51% upside
Graham Formula
$550.44
-3.5% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| UTHR | United Therapeutics Corpo… | $570.40 | 22.79B | -37% | -50% | -46% | -3% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
| BIIB | Biogen Inc. | $191.82 | 28.15B | +13% | -50% | -35% | -56% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| ILMN | Illumina, Inc. | $134.46 | 20.56B | -15% | -56% | -72% | -69% | 23.92 | 7.47 | 4.68 | 14.59 | — | 14.52 | 66.49% | 19.92% | 19.58% | 33.36% | 18.25% | 13.13% | 0.94 | 8.65 | 2.08 | 1.57 | 0.78 | -17074.00% | -69.00% | 3131.00% | 4.58% | 0.68 | 25.10% | 0.00% | 0.00% | 5.42% | 24.57 | 22.83 | 4.89 | 4.42 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| RPRX | Royalty Pharma plc | $46.21 | 19.8B | +84% | -35% | -81% | -50% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| THC | Tenet Healthcare Corporat… | $239.39 | 21.04B | -32% | -53% | -100% | -28% | 15.18 | 5.06 | 1.00 | 7.36 | — | -2.57 | 41.41% | 16.46% | 6.60% | 33.54% | 19.78% | 4.80% | 3.12 | — | 1.76 | 1.22 | 2.39 | -5263.00% | 312.00% | 12670.00% | 11.85% | 0.79 | 16.87% | 0.00% | 0.00% | 11.50% | 9.02 | 12.51 | 1.48 | 2.07 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
| WST | West Pharmaceutical Servi… | $254.34 | 18.32B | -20% | -57% | -75% | -62% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
- CEO
- Martine A. Rothblatt
- Employees
- 1.31K
- Beta
- 0.85
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($283.08 ÷ $570.40) − 1 = -50.37% (DCF, example).